| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000032995 |
| Receipt No. | R000037627 |
| Official scientific title of the study | A study to evaluate the safety of test foods for healthy adults. |
| Date of disclosure of the study information | 2018/06/14 |
| Last modified on | 2018/09/06 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | A study to evaluate the safety of test foods for healthy adults. | |
| Title of the study (Brief title) | A study to evaluate the safety of test foods. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy subjects | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the safety of ingestion of test foods for 4 weeks. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Physical, Hematologic, Blood biochemical, Urinalysis, Doctor' s questions, Weight before and 2, 4 weeks after intake and 2 weeks after the end of intake period and Adverse events thorough the study. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Dose comparison |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 4 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of test food 175 mg per day for 4 consecutive weeks | |
| Interventions/Control_2 | Intake of test food 350 mg per day for 4 consecutive weeks | |
| Interventions/Control_3 | Intake of test food 700 mg per day for 4 consecutive weeks | |
| Interventions/Control_4 | Intake of test food 1050 mg per day for 4 consecutive weeks | |
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Healthy males and females aged 20-64 years old | |||
| Key exclusion criteria | 1.Subjects who constantly use health food richly containing involvement ingredient
2.Subjects who have serious illness such as diabetes, liver disease, kidney disease, heart disease 3.Subjects who have possibilities for emerging allergy onset related to the study 4.Subjects with chronic illness or medication 5.Subjects with an irregular diet habit 6.Subjects who are judged as unsuitable for the study from clinical measurements for preliminary tests and measurements 7.Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies 8.Subjects who intend to become pregnant or lactating 9.Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire 10.Subjects who are judged as ineligible by clinical investigator |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Yasuhiro Sato |
| Organization | Shiratori Pharmaceutical Co., Ltd. |
| Division name | Research and Development Dept |
| Address | 6-11-24 Tsudanuma, Narashino-city, Chiba-pref |
| TEL | 047-453-2500 |
| y-sato@shiratori-pharm.co.jp | |
| Public contact | |
| Name of contact person | Kotoha Isobe |
| Organization | TTC Co., Ltd. |
| Division name | Clinical Research Planning Department |
| Address | Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo |
| TEL | 03-5459-5329 |
| Homepage URL | |
| k.isobe@ttc-tokyo.co.jp | |
| Sponsor | |
| Institute | TTC Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Shiratori Pharmaceutical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037627 |